Triglycerides

← Back to Lab Reference Library

Category: Metabolic Health  |  Also known as: TG, Triacylglycerol, Serum Triglycerides  |  Sample: Serum (12-hour fast required)

1. What This Test Measures

Triglycerides are the primary storage form of fatty acids in the body. Each triglyceride molecule consists of a glycerol backbone with three fatty acid chains attached. Triglycerides circulate in the bloodstream within lipoprotein particles: chylomicrons (carrying dietary fat absorbed from the intestine) and very low-density lipoproteins (VLDL, carrying triglycerides produced by the liver). A fasting triglyceride measurement eliminates the chylomicron contribution (which clears within 8 to 12 hours after eating) and reflects primarily hepatic VLDL production.

The critical distinction that most patients and many physicians miss: fasting triglycerides are not a measure of dietary fat intake. They are a measure of hepatic de novo lipogenesis, the process by which the liver converts excess carbohydrate and glucose into fatty acids, assembles them into triglycerides, packages them into VLDL particles, and exports them into the bloodstream. When carbohydrate intake exceeds the body's immediate energy needs and glycogen storage capacity, the liver converts the excess into fat. Elevated fasting triglycerides are therefore a marker of carbohydrate excess and insulin resistance, not a marker of eating too much fat.

This is why triglycerides often rise on low-fat, high-carbohydrate diets (more substrate for hepatic lipogenesis) and fall dramatically on low-carbohydrate, higher-fat diets (less substrate, improved insulin sensitivity). The standard dietary advice to "reduce fat to lower triglycerides" is physiologically backwards for most patients with elevated triglycerides.

2. Why This Test Matters

• Insulin resistance marker: elevated fasting triglycerides are one of the earliest and most sensitive lipid markers of insulin resistance. Triglycerides rise years before fasting glucose or HbA1c become abnormal because insulin-driven hepatic lipogenesis increases as the liver becomes insulin resistant
• TG/HDL ratio as a cardiovascular proxy: the TG/HDL ratio is the most accessible proxy for LDL particle size and insulin resistance. A ratio below 2.0 indicates large, buoyant LDL (Pattern A, lower risk). A ratio above 3.0 indicates small, dense LDL (Pattern B, higher risk) and significant metabolic dysfunction
• Non-alcoholic fatty liver disease (NAFLD): elevated triglycerides reflect increased hepatic lipogenesis, which is the mechanism driving fat accumulation in the liver. Triglycerides above 150 mg/dL should prompt evaluation for hepatic steatosis
• Cardiovascular risk: triglycerides are an independent cardiovascular risk factor. The triglyceride-rich remnant particles (produced as VLDL is metabolized) are directly atherogenic, contributing to plaque formation through arterial wall infiltration
• Pancreatitis risk: triglycerides above 500 mg/dL carry risk of acute pancreatitis, and levels above 1000 mg/dL represent a medical urgency requiring immediate lipid-lowering intervention
• Metabolic syndrome criterion: fasting triglycerides above 150 mg/dL is one of the five diagnostic criteria for metabolic syndrome (alongside elevated waist circumference, low HDL, elevated blood pressure, and elevated fasting glucose)
• Treatment response monitoring: triglycerides are the most diet-responsive lipid marker. A 30 to 50% reduction within 2 to 4 weeks of carbohydrate restriction confirms that dietary intervention is producing metabolic improvement

3. Standard Lab Reference Range

Triglyceride Level	Conventional Classification	Clinical Notes
Below 150 mg/dL	Normal	Standard threshold; functional medicine considers above 100 as suboptimal
150 to 199 mg/dL	Borderline high	Significant insulin resistance likely; dietary intervention indicated
200 to 499 mg/dL	High	Metabolic dysfunction confirmed; cardiovascular risk elevated
500 mg/dL or above	Very high	Pancreatitis risk; may require pharmacological intervention

4. Optimal Functional Medicine Range

Triglyceride Level	Functional Interpretation
Below 60 mg/dL	Excellent: optimal metabolic function and insulin sensitivity
60 to 80 mg/dL	Optimal: target range for functional medicine; indicates healthy hepatic metabolism
80 to 100 mg/dL	Acceptable: monitor trend; dietary refinement may further optimize
100 to 149 mg/dL	Suboptimal: conventionally "normal" but indicates early carbohydrate excess or insulin resistance
150 mg/dL or above	Elevated: confirmed metabolic dysfunction requiring active dietary intervention

5. Triglycerides in the Complete Metabolic Panel

Triglycerides are one component of a comprehensive metabolic and cardiovascular assessment:

Marker	What It Adds	FM Optimal
Triglycerides (this page)	Hepatic lipogenesis; carbohydrate metabolism status	Below 80 mg/dL
TG/HDL Ratio	LDL particle size proxy; insulin resistance index	Below 2.0
Fasting Insulin	Direct insulin resistance measurement	2 to 6 uIU/mL
HbA1c	90-day average glucose; lagging indicator	Below 5.4%
Fasting Glucose	Spot glucose; impaired fasting glucose detection	72 to 85 mg/dL
hs-CRP	Systemic inflammation; metabolic inflammation marker	Below 1.0 mg/L

6. Symptoms Associated With Elevated Triglycerides

7. What Causes Elevated Triglycerides

• Excess carbohydrate intake: the most common cause. Refined carbohydrates, added sugars, and ultra-processed foods provide substrate for hepatic de novo lipogenesis. Fructose is particularly triglyceride-producing because it is metabolized almost exclusively in the liver
• Insulin resistance: insulin resistance in the liver impairs the normal suppression of VLDL production by insulin, producing constitutively elevated VLDL and triglyceride output regardless of dietary intake
• Alcohol: alcohol is metabolized in the liver and preferentially drives triglyceride synthesis. Even moderate alcohol consumption (1 to 2 drinks daily) can elevate triglycerides in susceptible individuals
• Physical inactivity: skeletal muscle is a major site of triglyceride clearance through lipoprotein lipase (LPL) activity. Sedentary behavior reduces LPL expression and impairs triglyceride clearance
• Obesity: visceral adipose tissue drives insulin resistance and hepatic lipogenesis. Visceral fat reduction is one of the most effective triglyceride-lowering interventions
• Hypothyroidism: thyroid hormones regulate LPL expression and hepatic lipid metabolism. Hypothyroidism impairs triglyceride clearance and is an underdiagnosed cause of persistent hypertriglyceridemia
• Medications: beta-blockers, thiazide diuretics, corticosteroids, retinoids, estrogen therapy (oral), some HIV medications, and atypical antipsychotics all elevate triglycerides
• Genetic disorders: familial hypertriglyceridemia, familial combined hyperlipidemia, and lipoprotein lipase deficiency produce severe triglyceride elevation with a strong genetic component
• Renal disease: nephrotic syndrome produces elevated VLDL and triglycerides through increased hepatic lipoprotein synthesis

8. How to Lower Triglycerides

9. Related Lab Tests

10. When Testing Is Recommended

• Standard lipid panel component for all adults over 20 (NCEP guidelines recommend every 4 to 6 years; functional medicine recommends annually)
• Any patient with metabolic syndrome risk factors: abdominal obesity, hypertension, low HDL, elevated fasting glucose
• Monitoring dietary and lifestyle intervention for metabolic health: recheck at 4 to 8 weeks after initiating carbohydrate restriction to confirm response
• Patients with insulin resistance or type 2 diabetes: triglycerides are a primary metabolic marker
• Family history of cardiovascular disease, hypertriglyceridemia, or familial lipid disorders
• Patients on medications known to elevate triglycerides (beta-blockers, thiazides, corticosteroids, retinoids, oral estrogen)
• NAFLD evaluation and monitoring: triglycerides reflect the hepatic lipogenesis driving fatty liver
• Always evaluate alongside TG/HDL ratio, fasting insulin, and HbA1c for a complete metabolic picture

11. Clinical Perspective

12. Frequently Asked Questions